Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 06 02 2019
accepted: 24 04 2019
pubmed: 6 5 2019
medline: 18 1 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Germline mutations in checkpoint kinase 2 (CHEK2), a multiple cancer-predisposing gene, increase breast cancer (BC) risk; however, risk estimates differ substantially in published studies. We analyzed germline CHEK2 variants in 1,928 high-risk Czech breast/ovarian cancer (BC/OC) patients and 3,360 population-matched controls (PMCs). For a functional classification of VUS, we developed a complementation assay in human nontransformed RPE1-CHEK2-knockout cells quantifying CHK2-specific phosphorylation of endogenous protein KAP1. We identified 10 truncations in 46 (2.39%) patients and in 11 (0.33%) PMC (p = 1.1 × 10

Identifiants

pubmed: 31050813
doi: 10.1002/ijc.32385
doi:

Substances chimiques

Checkpoint Kinase 2 EC 2.7.1.11
CHEK2 protein, human EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1782-1797

Informations de copyright

© 2019 UICC.

Auteurs

Petra Kleiblova (P)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Lenka Stolarova (L)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Katerina Krizova (K)

Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.

Filip Lhota (F)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Jan Hojny (J)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Petra Zemankova (P)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Ondrej Havranek (O)

BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Michal Vocka (M)

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Marta Cerna (M)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Klara Lhotova (K)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Marianna Borecka (M)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Marketa Janatova (M)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Jana Soukupova (J)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Jan Sevcik (J)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Martina Zimovjanova (M)

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Jaroslav Kotlas (J)

Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Ales Panczak (A)

Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Kamila Vesela (K)

Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Jana Cervenkova (J)

Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Michaela Schneiderova (M)

First Department of Surgery, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Monika Burocziova (M)

Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.

Kamila Burdova (K)

Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.

Viktor Stranecky (V)

Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Lenka Foretova (L)

Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Eva Machackova (E)

Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

Spiros Tavandzis (S)

Department of Medical Genetics, AGEL Laboratories, AGEL Research and Training Institute, Novy Jicin, Czech Republic.

Stanislav Kmoch (S)

Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Libor Macurek (L)

Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.

Zdenek Kleibl (Z)

Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH